Rifaximin: 5 agencies, 2012–2025
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
No agency in this archive has refused rifaximin: all 7 decisive outcomes across 5 agencies were positive or positive with restrictions.
The file has been open for more than a decade: 12.8 years separate the first record, 27 Jul 2012 at AWMSG (Wales), from the most recent, 23 Apr 2025 at HAS (France).
No assessment is on file from PBAC (Australia), TLV (Sweden), CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
Not every gap is a refusal: for rifaximin, 1 submission was never made — an outcome set by the company rather than the assessor.
4 distinct indication wordings are recorded for rifaximin by the agencies that label one in English (AWMSG, NICE and SMC).
AWMSG (Wales) was first to assess rifaximin, on 27 Jul 2012; HAS (France) did not open a file until 18 Nov 2015 — a wide spread of 3.3 years between the earliest and latest system to look at it.
3 of the 5 agencies here assessed rifaximin more than once, HAS (France) most often at 3 entries — repeat review is the norm for this molecule rather than the exception.
Coverage is narrow: only 5 of the 18 agencies here have assessed rifaximin.
The full ledger for rifaximin reads 7 recommended, 1 deferred to NICE and 1 non-submission.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HAS (France) | 23 Apr 2025 | Re-assessment of SMR and ASMR | SMR substantial · ASMR IV | source |
| NICE (England) | 25 Mar 2015 | NICE TA337 | recommended | source |
| PHARMAC (New Zealand) | 6 Nov 2014 | Hepatic encephalopathy - 2nd line | PTAC advice: Recommended alteration to access criteria · decision reached | source |
| AWMSG (Wales) | 12 Nov 2012 | Reduction in recurrence of episodes of overt hepatic encephalopathy in patients ≥ 18 years of age | excluded, NICE appraised | source |
| SMC (Scotland) | 13 Aug 2012 | Treatment of travellers' diarrhoea. | not recommended | source |
4 further decisions for rifaximin, across 3 agencies, are not shown here. They link to 2 further source documents.
Related molecules
- fidaxomicin — same ATC class A07A — Antidiarrheals / intestinal anti-inflammatories
- vancomycin — same ATC class A07A — Antidiarrheals / intestinal anti-inflammatories
- osimertinib — also decided by HAS in 2025Q2
- ofatumumab — also decided by HAS in 2025Q2
- efgartigimod alfa — also decided by HAS in 2025Q2
- risdiplam — also decided by HAS in 2025Q2
Coverage: 9 decisions for rifaximin from 5 agencies, 2012 to 2025. Data to 7 Sep 2026. ATC class A07A — Antidiarrheals / intestinal anti-inflammatories. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.